Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity (2023 - 2025)

Historic Common Equity for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $687.6 million.

  • CG Oncology's Common Equity rose 2810.76% to $687.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $687.6 million, marking a year-over-year increase of 2810.76%. This contributed to the annual value of $733.4 million for FY2024, which is 69575.71% up from last year.
  • As of Q3 2025, CG Oncology's Common Equity stood at $687.6 million, which was up 2810.76% from $670.4 million recorded in Q2 2025.
  • CG Oncology's Common Equity's 5-year high stood at $733.4 million during Q4 2024, with a 5-year trough of -$123.1 million in Q4 2023.
  • Its 3-year average for Common Equity is $541.4 million, with a median of $619.6 million in 2024.
  • In the last 5 years, CG Oncology's Common Equity soared by 69575.71% in 2024 and then soared by 2136.27% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Common Equity stood at -$123.1 million in 2023, then skyrocketed by 695.76% to $733.4 million in 2024, then fell by 6.24% to $687.6 million in 2025.
  • Its last three reported values are $687.6 million in Q3 2025, $670.4 million for Q2 2025, and $704.8 million during Q1 2025.